Cargando…
Erratum to: Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction – a randomised placebo-controlled trial (KARE): study protocol
Autores principales: | Cross, Laurence J. M., O’Kane, Cecilia M., McDowell, Cliona, Elborn, Jospeh J., Matthay, Michael A., McAuley, Daniel F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425974/ https://www.ncbi.nlm.nih.gov/pubmed/28494790 http://dx.doi.org/10.1186/s13063-017-1930-7 |
Ejemplares similares
-
Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction – a randomised placebo-controlled trial (KARE): study protocol
por: Cross, Laurence JM, et al.
Publicado: (2013) -
The relationship between plasma cystatin C, mortality and acute respiratory distress syndrome subphenotype in the HARP-2 trial
por: McKelvey, Michael C., et al.
Publicado: (2023) -
Simvastatin for patients with acute respiratory distress syndrome: long-term outcomes and cost-effectiveness from a randomised controlled trial
por: Agus, A., et al.
Publicado: (2017) -
Erratum to: ‘Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial’
por: Hellyer, Thomas P., et al.
Publicado: (2016) -
Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial
por: Gorman, Ellen, et al.
Publicado: (2022)